Holen Sie sich die Stockscreener-App
0.3552
5.53%
-0.0208
Handel nachbörslich:
.35
-0.0052
-1.46%
Schlusskurs vom Vortag:
$0.376
Offen:
$0.3777
24-Stunden-Volumen:
1.36M
Relative Volume:
1.92
Marktkapitalisierung:
$4.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.26M
KGV:
-0.0609
EPS:
-5.83
Netto-Cashflow:
$-8.25M
1W Leistung:
+7.64%
1M Leistung:
+23.33%
6M Leistung:
-75.50%
1J Leistung:
-93.02%
1-Tages-Spanne:
$0.3199
$0.395
1-Wochen-Bereich:
$0.3199
$0.448
52-Wochen-Spanne:
$0.2542
$7.74
Oragenics Inc Stock (OGEN) Company Profile
Firmenname
Oragenics Inc
Sektor
Branche
Telefon
813-286-7900
Adresse
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Vergleichen Sie OGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.3552 | 4.34M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oragenics Inc Aktie (OGEN) Neueste Nachrichten
Oragenics Simplifies Capital Structure and Advances Strategy - TipRanks
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - The Manila Times
Oragenics Strengthens Balance Sheet: $2.35M Preferred Share Conversion Streamlines Capital Structure - StockTitan
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics director Alan Dunton sells $23 in common stock By Investing.com - Investing.com Canada
Oragenics director Alan Dunton sells $23 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock - Investing.com
Oragenics director Fred Telling sells $1,294 in common stock By Investing.com - Investing.com UK
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2024. - Marketscreener.com
Oragenics announces termination of president's employment agreement By Investing.com - Investing.com South Africa
Oragenics announces termination of president's employment agreement - Investing.com India
Oragenics : Termination of Material Agreement Form 8 K - Marketscreener.com
Mice Model Market: Global Type, Trends, Service, Growth, - openPR
OGEN Stock Plummets to 52-Week Low at $0.28 Amid Steep Decline - Investing.com Australia
OGEN Stock Plummets to 52-Week Low at $0.28 Amid Steep Decline By Investing.com - Investing.com South Africa
500: Something went wrong - Investing.com India
Oragenics: Q3 Earnings Snapshot - The Pioneer
Oral Probiotics Supplements Market Expected to Experience - openPR
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World
SEC Form DEF 14A filed by Oragenics Inc. - Quantisnow
OGEN stock plunges to 52-week low, touches $0.28 By Investing.com - Investing.com Australia
OGEN stock plunges to 52-week low, touches $0.28 - Investing.com
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury
Oragenics, Inc. to Present at the Centurion One Capital 2nd Annual Bahamas Summit - Marketscreener.com
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - GlobeNewswire
Check Out Oragenics Inc (OGEN)’s Trade Data Rather Than the Analysts’ Views - SETE News
Oragenics Shares Investor Presentation Online - TipRanks
Oragenics inks sales agreement for at-the-market stock offering - Investing.com
Oragenics inks sales agreement for at-the-market stock offering By Investing.com - Investing.com South Africa
Oragenics Inc (OGEN) stock analysis: A comprehensive overview - US Post News
The Future of Oragenics Inc: Analyzing OGEN - The InvestChronicle
Oragenics advances concussion treatment with ONP-002 By Investing.com - Investing.com South Africa
Oragenics advances concussion treatment with ONP-002 - Investing.com India
Metric Deep Dive: Understanding Oragenics Inc (OGEN) Through its Ratios - The Dwinnex
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation - GlobeNewswire
OGEN stock touches 52-week low at $0.37 amid sharp annual decline - Investing.com India
OGEN’s valuation metrics: A comprehensive analysis - US Post News
Finanzdaten der Oragenics Inc-Aktie (OGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):